

# Reviews in Pain

<http://bjp.sagepub.com/>

---

## Recent Advancements in Temporomandibular Disorders (TMDs)

J Durham and RW Wassell  
*Reviews in Pain* 2011 5: 18  
DOI: 10.1177/204946371100500104

The online version of this article can be found at:  
<http://bjp.sagepub.com/content/5/1/18>

---

Published by:



<http://www.sagepublications.com>

On behalf of:



THE BRITISH PAIN SOCIETY

[British Pain Society](#)

Additional services and information for *Reviews in Pain* can be found at:

**Email Alerts:** <http://bjp.sagepub.com/cgi/alerts>

**Subscriptions:** <http://bjp.sagepub.com/subscriptions>

**Reprints:** <http://www.sagepub.com/journalsReprints.nav>

**Permissions:** <http://www.sagepub.com/journalsPermissions.nav>

**Citations:** <http://bjp.sagepub.com/content/5/1/18.refs.html>

>> [Version of Record](#) - Mar 1, 2011

[What is This?](#)

# Recent advancements in Temporomandibular Disorders (TMDs)

J Durham PhD BDS MFDS RCS (Ed) FHEA

NIHR Academic Clinical Lecturer in Oral Surgery

RW Wassell PhD BDS FDS RCS

Senior Lecturer/Hon Consultant in Restorative Dentistry

School of Dental Sciences, Newcastle University, United Kingdom.

## SUMMARY POINTS

- TMDs are a group of conditions affecting the joint and or the muscles of mastication.
- TMDs consist of three main groups of conditions: myofascial pain; disc disorders; TMJ arthritides.
- The gold standard diagnostic criteria for research involving TMDs are the Research Diagnostic Criteria for TMDs (RDC/TMD). A pragmatic clinically applicable alternative is the Clinical examination protocol for TMDs (CEP-TMD).
- Signs and symptoms can include: pain in masticatory musculature and or the joint; noises associated with joint movements; locking; headache; otalgia.
- TMDs' aetiology is multifactorial and biopsychosocial in nature.
- Reversible conservative management as defined by the American Association of Dental Research is the initial management of choice for all subgroups of TMDs.

## Introduction

Temporomandibular disorders (TMDs) have been known by many other previous names and debate over their classification is still ongoing<sup>1</sup>. It is appropriate at this point to highlight that TMDs is not a singular description<sup>1</sup> but a collective term describing a group of conditions affecting either the temporomandibular joint (TMJ), the masticatory musculature, or both.

TMDs can present with a multitude of signs and symptoms, which can sometimes be confusing to both the patient and clinician. The

usual age group for presentation is in the second to fourth decades and despite the prevalence of TMDs being almost equal in the genders, females present clinically much more often<sup>2</sup>. The signs and symptoms of TMDs (Table 1) are familiar to dentists but not always to doctors.

The most common of the conditions comprising TMDs are readily diagnosable using criteria such as the Research Diagnostic Criteria for TMDs (RDC/TMD)<sup>3</sup>:

- Myofascial pain
  - Myofascial pain with limited opening
  - Myofascial pain without limited opening
- TMJ Disc displacements
  - Disc displacement with reduction (*characterised by reproducible clicking*)

**Table 1** Signs and symptoms of Temporomandibular Disorders

Pain in masticatory musculature and or joint which can radiate and refer
"Locking" – can refer to closed lock, inability to open fully, or open lock, dislocation
Noises associated with movement of the joint: clicking or crepitus
Headache
Generalised "tightness" around face in the morning
Otalgia

- Disc displacement without reduction with limited opening (*characterised by a “closed lock”*)
- Disc displacement without reduction without limited opening
- TMJ Arthritides
  - Osteoarthritis
  - Osteoarthrosis
  - Arthralgia

Previous terminology for TMDs that is now superseded and largely falling into disuse includes: Facial Arthromyalgia, Pain-Dysfunction syndrome, TMJ, and temporomandibular joint dysfunction.

The aim of this paper is to discuss recent advances in the aetiology, diagnosis and management of TMDs

### Aetiology

The aetiology of TMDs has been the subject of much debate over the years. Some of the debate has been scientific and some of it has been based on anecdote or experience. The aetiology of TMDs is regarded traditionally as multifactorial with predisposing, precipitating and prolonging factors, which conspire together variously in different patients. In reality, the aetiology of TMDs is still unclear with some suggesting that because of their link with other functional somatic syndromes TMDs may form part of the same phenomenon<sup>4</sup>. Clearly, patients with TMDs do present with psychological disorders but it is difficult to prove whether they are causative, or a result of the TMDs<sup>5</sup>.

Much attention over the years has been paid to the way the teeth occlude (bite together). In most patients, however, occlusion has not been shown to have a strong enough causal relationship to be considered a general aetiological factor<sup>6</sup>. Reconstruction of the occlusion (occlusal rehabilitation, or occlusal equilibration) of the teeth is not therefore indicated in the majority of cases.

Potential breakthroughs have, however, recently occurred in understanding the possible physiological and genetic basis for some of the pain associated with TMDs. Recent data suggest that there may be adrenergic dysregulation in TMDs, which would help to account for their fluctuating nature especially during times of stress<sup>7</sup>. Further to this a US group based in North Carolina have been extensively investigating haplotypes of the gene encoding catecholamine-O-methyl-transferase (COMT).

Their findings suggest:

- 1) That COMT activity varies according to the three major haplotypes they have identified (low pain sensitivity, average pain sensitivity, high pain sensitivity)<sup>8</sup>
- 2) That haplotypes of the gene producing less COMT activity are associated with development of TMD and increased experimental pain sensitivity<sup>8,9</sup>
- 3) Decreased COMT activity increases pain sensitivity through increased levels of circulating catecholamines activating  $\beta_2$  and  $\beta_3$  adrenergic receptors<sup>9</sup>
- 4) That COMT haplotype and psychological characteristics independently increase the risk of clinical pain<sup>10</sup>
- 5) That the relative risk of TMD associated with orthodontic treatment (which can act as an irritant through direct pressure on the teeth and changing the way the teeth occlude) was dependent on the pain sensitive haplotype of the gene encoding COMT<sup>11</sup>.

The final development from this large programme of work is a proof-of-concept study using Propranolol versus placebo in patients suffering from TMDs with varying numbers of low-pain sensitivity alleles<sup>12</sup>. The sample tested included patients with TMDs, which were diagnosed by the RDC/TMD either as myofascial pain, or as myofascial pain with arthralgia. All participants had been experiencing pain for more than three months. A lower number of low-pain sensitivity alleles were significantly associated with greater net change in the pain index when low-dose propranolol was administered (20mg bd). Given that propranolol's mechanism of action is through non-selective antagonism of beta-receptors (Beta-1 and Beta-2) its positive effect on reducing the pain index would seemingly substantiate the potential role of circulating catecholamines on pain in TMDs.

Unsurprisingly the same group are helping lead the multi-million dollar OPPERA study in the U.S. (**O**rofacial **P**ain: **P**rospective **E**valuation and **R**isk **A**ssessment: <https://www.oppera.org/>). This prospective large cohort-type study seeks to examine and catalogue baseline physical and psychological data, including genotyping, on thousands of volunteers to attempt, for the first time, to prospectively identify risk factors and predictors for the myofascial and arthritides TMDs. One potential risk factor recently determined by genetics is that a polymorphism of the oestrogen alpha-receptor leads to a three-fold increase in risk of developing a painful TMD and a two-fold risk of developing a non-painful TMD as diagnosed by the RDC/TMD. It is possible that oestrogen influences the pain felt in TMDs through an effect on the Dopamine system<sup>13</sup> and degenerative disease through modulation of cellular responses in the TMJ<sup>14</sup>.

Research on the aetiology of osteoarthritis and disc disorders in the TMJ has focussed largely on the role of protracted or excessive mechanical stress. This type of mechanical stress can be produced

in a number of ways but one of the more common mechanisms is parafunction (excessive clenching or grinding of teeth). It is suggested that protracted or excessive mechanical stress can result in the production of free radicals through a number of mechanisms<sup>14-16</sup>:

- homolytic fission through shear stress within articular tissues
- microbleeding into joint space leading to producing Ferryl radicals
- phospholipid catabolism caused by shear stress
- hypoxia-reperfusion injury – pressure created when mechanical stress exceeds end capillary pressure thereby causing a shift in cell metabolism
- stimulation of neuropeptide release giving rise to neurogenic inflammation causing further microbleeding.

A number of factors can then impair the normal scavenging system for free radicals in the TMJ system including: genotype, nutritional deficiency, or compromised synthesis of scavengers due to cells being mechanically stressed<sup>14</sup>. If the scavenging system is compromised there will be excess free radicals within the TMJ system<sup>17,18</sup>. Within the literature there are a number of hypotheses and some data to suggest that free radicals may exert a number of effects on the TMJ articular system<sup>14-16, 19-27</sup> (Table 2).

A particularly important effect of free radicals is the inhibition of hyaluronic acid synthesis. The lubrication system of the TMJ relies on free full fluid film provided through hyaluronic acid's highly viscous nature, and boundary lubrication to allow the joint and its disc to move smoothly and synchronously. Hyaluronic acid also helps protect the phospholipids present on the articular surfaces which form part of the boundary lubrication system. The decreased levels of hyaluronic acid make these phospholipids more prone to lysis by

Phospholipase A2<sup>21</sup>. In health, the phospholipids' non-polar ends are exposed to the joint space creating a low friction surface through their hydrophobic nature (boundary lubrication). The degradation of the phospholipids by Phospholipase A2 results in a surface with higher friction and adhesive properties<sup>21, 28, 29</sup> and it has been suggested that this can result in an anchored disc phenomenon.

Anchored disc phenomenon is suggested to be present when the articular disc is adhered to the glenoid fossa and renders the condyle unable to translate producing a considerable reduction in mouth opening suggested to be much more pronounced than disc displacement without reduction with limited opening and not necessarily preceded by clicking<sup>19</sup>. It is possible, however, that disc displacement without reduction and anchored disc phenomenon may be differing stages of the same clinical entity and distinguishing between them on clinical and radiological investigations may be somewhat subjective. The major difference asserted between the two is the very positive response of an anchored disc to arthrocentesis<sup>19</sup>.

**Diagnosis**

In routine clinical practice diagnosis of TMDs has largely depended on a careful history and clinical exam with imaging, ionising or otherwise, playing a limited role. Electronic devices such as jaw tracking, vibratography, sonography have insufficient evidence to suggest their use as diagnostic devices<sup>30</sup>. Imaging of the temporomandibular complex is also not without its limitations in the main due to false positives: condylar shape and osseous changes on plain radiographs can occur in asymptomatic individuals and have little bearing on treatment<sup>31, 32</sup>; asymptomatic individuals have been shown to have disc displacements or joint effusions on MRI<sup>33-37</sup>. Cone-beam and computed tomography have been shown to have good sensitivity and specificity for osseous changes but evidence-based indications for their use have still to be determined<sup>37</sup>. Ultrasound is now being used to image the Temporomandibular complex and has varying sensitivity and specificity but maybe an area of future development<sup>38</sup>, but at present imaging within the scope of TMDs is probably best employed as an adjunct to clinical diagnosis as opposed to a definitive diagnostic test.

In the research setting there was a need to reliably select homogenous samples to trial interventions. Clinical examination did not always fulfil the rigorous requirements for sample selection. The introduction of the RDC/TMD criteria in 1992 helped solve this problem and allowed researchers for the first time to be certain they were selecting samples with a reliable and valid diagnostic instrument<sup>3</sup>.

The RDC/TMD has not, however, formed part of routine clinical practice within the UK perhaps largely due to an unfair reputation of being complex and somewhat time-consuming. Efforts have recently been made to simplify and shorten the RDC/TMD criteria for routine busy clinical practice<sup>39</sup>. This has produced a clinical examination protocol (CEP-TMD), which produces as reliable diagnoses in the same diagnostic categories as the RDC/TMD

**Table 2 Potential actions of free radicals on TMJ articular system**

1) Free radicals are proposed to damage the biomechanical properties of the articular tissues. The damaged articular tissues are then more susceptible to any further mechanical stresses placed upon them. This vicious circle is continued by the release of extracellular matrix degradation products from the damaged articular tissue. These degradation products attract inflammatory cells resulting in the release of cytokines that help further degrade the articular tissues <sup>15</sup> .
2) Alongside mechanical stress, free radicals present in the joint space can stimulate the release of neuropeptides and Nitric Oxide from peripheral sensory nerve endings <sup>23, 25, 26, 69</sup> . The neuropeptides and Nitric oxide help increase the localised inflammatory response within the TMJ system and thereby contribute to further damaging the articular tissues through production of further free radicals and cytokines.
3) Free radicals can help produce adhesions within the joint space <sup>24,27</sup> .
4) Free radicals play a role in changing the lubrication system within the TMJ through inhibiting hyaluronic acid synthesis and facilitating the degradation of the articular surfaces' phospholipids <sup>19</sup> .

but in significantly quicker examination times. The CEP-TMD is available for download and viewing at [www.ncl.ac.uk/dental/AppliedOcclusion/](http://www.ncl.ac.uk/dental/AppliedOcclusion/). The RDC/TMD is currently undergoing revision for two purposes: (1) to provide a new updated RDC; (2) to provide a version, which is applicable in the everyday clinical setting<sup>40</sup>.

Red flag signs and symptoms that might suggest a more sinister condition is mimicking TMDs include:

- Cranial nerve dysfunction especially in cranial nerves<sup>1, 5, 7, 8</sup>
- Late onset (>50) sudden profound limitation in mouth opening
- Recurrent epistaxis or discharge from nose
- Ipsilateral lymphadenopathy.

TMDs may occasionally present as part of a systemic condition affecting the joints, muscles or ligaments. Examples include rheumatoid arthritis, fibromyalgia and systemic joint laxity. As well as diagnosing the type of TMD it is also important to determine if such systemic conditions are present and properly addressed rather than manage TMD in isolation.

### Management

Since the late 1970s it has been identified that patients with TMDs have a high placebo response rate and evidence has emerged over the generic biologically real effect of the placebo<sup>41-47</sup>. A recent paper has discussed the need to ethically and morally harness that biologically real effect within therapeutic interactions with TMDs patients without giving a placebo per se<sup>48</sup>.

The paucity of high quality evidence on which to base management of TMDs is one of the main reasons that the American Association of Dental Research has issued a new scientific statement indicating reversible conservative therapy, for instance basic intra-oral appliances, biobehavioural therapy, physiotherapy, simple analgesia, as the initial management of TMDs<sup>49</sup>.

Pharmacological management targeted to the pathophysiology of TMDs has been examined recently by two systematic reviews. The conclusions of the reviews were that pharmacological management of TMDs is largely empirical and there is a need to perform research to further establish key pathophysiological mechanisms in TMDs that would be suitable targets for pharmacological agents<sup>50, 51</sup>. There has been a recent promising trial of gabapentin in myofascial pain that shows a significant effect on pain although the effect may only be over a short time span<sup>52</sup>.

A recent systematic review<sup>53</sup> of all relevant systematic reviews of management of TMDs drew the following conclusions:

- Occlusal appliances, acupuncture, behavioural therapy, and jaw exercises have some evidence showing they are effective in alleviating pain for patients with TMDs
- Occlusal adjustment appears to have no evidence supporting a therapeutic effect and has the disadvantage of being irreversible
- There is insufficient evidence to support surgical or electrophysical interventions in TMDs.

Similarly to occlusal adjustment orthodontic treatment has previously been used in the management of TMDs. A recent Cochrane review has, however, highlighted the lack of evidence to support or refute orthodontics as a preventative or therapeutic modality for TMDs and has suggested that orthodontics cannot, therefore be recommended as a treatment either to prevent, or relieve, TMDs<sup>54</sup>.

The results of meta analyses such as those cited in the previous paragraph need to be interpreted with care so that a treatment which shows no therapeutic effect when used in a general population of TMDs is not withheld from TMDs patients who have a specific need and who have not responded to conservative management. For example, occlusal adjustment is certainly no better than placebo when used as a general primary treatment for a TMD, but if the TMD began at the placement of a recent restoration and this restoration is shown to create an occlusal interference it would be warranted to adjust this restoration. In this sort of a situation the occlusion may be a precipitating or a prolonging factor, which may exacerbate a TMD in patients predisposed to TMDs. The most important matter in these cases is that there needs to be a very good clinical indication to embark on irreversible treatment, this indication should be documented and its disadvantages fully discussed with the patient.

Whilst conservative management strategies should always be considered the first line of management of TMDs it is important to highlight the development of interest in TMJ surgical corrections. In this way the specialist pain team members can keep abreast of developments in this area. Surgical procedures for the TMJ include arthrocentesis, arthroscopy, open joint procedures, and total joint replacement. Arthrocentesis is the most minimally invasive of the four options but has the disadvantage of being a “blind” procedure only allowing lysis and lavage. Arthroscopy has the added benefit of being able to visualise the interior of the joint capsule, usually the upper joint space. This visualisation has led some to suggest it aids diagnosis as well as providing a therapeutic benefit. One meta-analysis has found it impossible to demonstrate a therapeutic advantage of arthroscopy over arthrocentesis<sup>55</sup>, but another meta-analysis has highlighted the lack of evidence to support or refute the use of arthrocentesis in TMDs involving some form of internal derangement<sup>56</sup>. The best summary of both of these meta-analyses is that the current evidence base is of a poor quality and further work is required to help determine the indications for arthrocentesis and arthroscopy.

Both arthroscopy and arthrocentesis can be used to introduce medications into the joint capsule. Other than analgesics or anaesthetics, one of the more extensively examined medications is sodium hyaluronate. A group of European researchers have produced promising results with Sodium hyaluronate in combination with arthrocentesis for osteoarthritis of the TMJ<sup>57-63</sup>. Unfortunately though the level of evidence is still insufficient for recent systematic reviews to draw firm conclusions about Sodium hyaluronate's efficacy in the arthritides and disc disorders sub-classification of TMDs<sup>64,65</sup>.

In recent years since the advent of arthroscopy open joint procedures have received less attention in the literature, but there has been a recent and limited resurgent interest in Temporomandibular joint replacement<sup>66,67</sup>. This resurgent interest has led NICE to issue guidelines based on expert and patient opinion, and the current evidence base<sup>68</sup>. The British Association of TMJ Surgeons clearly state that this is a procedure to be carried out in end stage **disease** and has **few actual indications** within the spectrum of conditions comprising TMDs. There is also a danger that in patients with a degree of central sensitisation as a result of chronic pain related to TMDs such an acute insult to the peripheral nociceptive system might produce a further decline in their quality of life and pain management.

## Conclusion

There are some exciting new advances in understanding the pathophysiology of TMDs and the ongoing OPPERA study will further advance our understanding. At the current time patients suffering from TMDs still need a biopsychosocial approach to management, which may need to be carefully tailored in patients not responding to conservative management. In the future it may be possible to determine indications for treatment and target treatments on a genetic basis.

## REFERENCES

1. Laskin DM. Temporomandibular disorders: a term past its time? *Journal of the American Dental Association* 2008;139 (2) 124-128
2. Gray RJ, Davies SJ, Quayle AA. A clinical approach to temporomandibular disorders. 1. Classification and functional anatomy. *British Dental Journal* 1994; 176 (11) 429-435
3. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique *Journal of Craniomandibular Disorders*. 1992; 6 (4) 301-355
4. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? *The Lancet* 1999; 354 (9182) 936-939
5. Ohrbach R, Dworkin SF. Five-year outcomes in TMD: relationship of changes in pain to changes in physical and psychological variables. *Pain*. 1998; 74 (2-3) 315-326
6. Laskin DM, Greene CS, Hylander WL. *Temporomandibular disorders : an evidence-based approach to diagnosis and treatment*. Chicago: Quintessence Pub.; 2006:xii, 548
7. Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, Maixner W. Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. *Journal of Pain*. 2009; 10 (5) 542-552
8. Diatchenko L, Slade GD, Nackley AG et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. *Human Molecular Genetics* 2005; 14 (1) 135-143
9. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. *Pain* 2007; 128 (3) 199-208
10. Slade GD, Diatchenko L, Bhalang K et al. Influence of psychological factors on risk of temporomandibular disorders *Journal of Dental Research* 2007; 86 (11) 1120-1125
11. Slade GD, Diatchenko L, Ohrbach R, Maixner W. Orthodontic Treatment, Genetic Factors and Risk of Temporomandibular Disorder *Seminars in Orthodontics* 2008; 14 (2) 146-156
12. Tchivileva IE, Lim PF, Smith SB et al. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study *Pharmacogenetics and Genomics* 2010; 20 (4) 239-248
13. Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley J Jr. Sex, gender, and pain: a review of recent clinical and experimental findings *Journal of Pain* 2009;10 (5) 447-485
14. Milam SB. Pathogenesis of degenerative temporomandibular joint arthritides *Odontology* 2005; 93 (1) 7-15
15. Milam SB, Zardeneta G, Schmitz JP. Oxidative stress and degenerative temporomandibular joint disease: a proposed hypothesis *Journal of Oral and Maxillofacial Surgery* 1998; 56 (2) 214-223
16. Haskin CL, Milam SB, Cameron IL. Pathogenesis of degenerative joint disease in the human temporomandibular joint *Critical Reviews in Oral Biology and Medicine* 1995; 6 (3) 248-277

17. Cai HX, Luo JM, Long X, Li XD, Cheng Y. Free-radical oxidation and superoxide dismutase activity in synovial fluid of patients with temporomandibular disorders *Journal of Orofacial Pain* 2006; 20 (1) 53-58
18. Guven O, Tekin US, Durak I, Keller EE, Hatipoglu M. Superoxide dismutase activity in synovial fluids in patients with temporomandibular joint internal derangement *Journal of Oral and Maxillofacial Surgery* 2007; 65 (1) 1940-1943
19. Nitzan DW, Etsion I. Adhesive force: the underlying cause of the disc anchorage to the fossa and/or eminence in the temporomandibular joint--a new concept *International Journal of Oral and Maxillofacial Surgery* 2002; 31 (1) 94-99
20. Nitzan DW, Goldfarb A, Gati I, Kohen R. Changes in the reducing power of synovial fluid from temporomandibular joints with "anchored disc phenomenon" *Journal of Oral and Maxillofacial Surgery* 2002; 60 (7) 735-740
21. Nitzan DW, Nitzan U, Dan P, Yedgar S. The role of hyaluronic acid in protecting surface-active phospholipids from lysis by exogenous phospholipase A(2). *Rheumatology (Oxford)*. 2001; 40 336-340
22. Rahamim E, Better H, Dagan A, Nitzan DW. Electron microscope and biochemical observations of the surface active phospholipids on the articular surfaces and in the synovial fluid of the temporomandibular joint: a preliminary investigation *Journal of Oral and Maxillofacial Surgery* 2001; 59 (11) 1326-1332
23. Takahashi T, Kondoh T, Kamei K et al. Elevated levels of nitric oxide in synovial fluid from patients with temporomandibular disorders. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 1996; 82 (5) 505-509
24. Dijkgraaf LC, Zardeneta G, Cordewener FW et al. Crosslinking of fibrinogen and fibronectin by free radicals: a possible initial step in adhesion formation in osteoarthritis of the temporomandibular joint. *Journal of Oral and Maxillofacial Surgery* 2003; 61 (1) 101-111
25. Holmlund A, Ekblom A, Hansson P, Lind J, Lundberg T, Theodorsson E. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and arthroscopic findings. *International Journal of Oral and Maxillofacial Surgery* 1991; 20 (4) 228-231
26. Sato J, Segami N, Kaneyama K, Yoshimura H, Fujimura K, Yoshitake Y. Relationship of calcitonin gene-related peptide in synovial tissues and temporomandibular joint pain in humans *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2004; 98 (5) 533-540
27. Sheets DW Jr., Okamoto T, Dijkgraaf LC, Milam SB, Schmitz JP, Zardeneta G. Free radical damage in facsimile synovium: correlation with adhesion formation in osteoarthritic TMJs *Journal of Prosthodontics* 2006;15 (1) 9-19
28. Hills BA. Synovial surfactant and the hydrophobic articular surface. *Journal of Rheumatology* 1996; 23 (8) 1323-1325
29. Hills BA. Boundary lubrication in vivo *Proceedings of the Institutes of Mechanical Engineers. Part H* 2000; 214 (1) 83-94
30. Greene CS. An evaluation of unconventional methods of diagnosing and treating Temporomandibular Disorders. *Oral and Maxillofacial Surgery Clinics of North America* 1995; (7) 167-173
31. Crow HC, Parks E, Campbell JH, Stucki DS, Daggy J. The utility of panoramic radiography in temporomandibular joint assessment. *Dento maxillo facial Radioogy*. 2005; 34 (2) 91-95
32. Epstein JB, Caldwell J, Black G. The utility of panoramic imaging of the temporomandibular joint in patients with temporomandibular disorders. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2001; 92 (2) 236-239
33. Larheim TA, Westesson P, Sano T. Temporomandibular joint disk displacement: comparison in asymptomatic volunteers and patients. *Radiology* 2001; 218 (2) 428-432
34. Larheim TA, Katzberg RW, Westesson PL, Tallents RH, Moss ME. MR evidence of temporomandibular joint fluid and condyle marrow alterations: occurrence in asymptomatic volunteers and symptomatic patients *International Journal of Oral Maxillofacial Surgery* 2001; 30 (2) 113-117
35. Kircos LT, Ortendahl DA, Mark AS, Arakawa M. Magnetic resonance imaging of the TMJ disc in asymptomatic volunteers *Journal of Oral and Maxillofacial Surgery* 1987; 45 (10) 852-854
36. Limchaichana N, Petersson A, Rohlin M. The efficacy of magnetic resonance imaging in the diagnosis of degenerative and inflammatory temporomandibular joint disorders: a systematic literature review *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2006;102 (4) 521-536
37. Petersson A. What you can and cannot see in TMJ imaging - an overview related to the RDC/TMD diagnostic system *Journal of Oral Rehabilitation* 2010; 37 (10) 771-778
38. Melis M, Secci S, Ceneviz C. Use of ultrasonography for the diagnosis of temporomandibular joint disorders: a review *American Journal of Dentistry* 2007; 20 (22) 73-78
39. Hasanain F, Durham J, Moufti A, Steen IN, Wassell RW. Adapting the diagnostic definitions of the RDC/TMD to routine clinical practice: a feasibility study *Journal of Dentistry* 2009; 37 (12) 955-962

40. List T, Greene CS. Moving forward with the RDC/TMD *Journal of Oral Rehabilitation* 2010; 37 (10) 731-733
41. Goodman P, Greene CS, Laskin DM. Response of patients with myofascial pain-dysfunction syndrome to mock equilibration. *Journal of the American Dental Association* 1976; 92 (4) 755-758
42. Greene CS, Laskin DM. Meprobamate therapy for the myofascial pain-dysfunction (MPD) syndrome: a double-blind evaluation *Journal of the American Dental Association* 1971; 82 (3) 587-590
43. Greene CS, Laskin DM. Splint therapy for the myofascial pain-dysfunction (MPD) syndrome: a comparative study *Journal of the American Dental Association* 1972; 84 (3) 624-628
44. Greene CS, Laskin DM. Long-term evaluation of conservative treatment for myofascial pain-dysfunction syndrome *Journal of the American Dental Association* 1974; 89 (6) 1365-1368
45. Laskin DM, Greene CS. Influence of the doctor-patient relationship on placebo therapy for patients with myofascial pain-dysfunction (MPD) syndrome *Journal of the American Dental Association* 1972; 85 (4) 892-894
46. Shipman WG, Greene CS, Laskin DM. Correlation of placebo responses and personality characteristics in myofascial pain-dysfunction (MPD) patients *Journal of Psychosomatic Research* 1974; 18 (6) 475-483
47. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects *The Lancet* 2010; 375 (9715) 686-695
48. Greene CS, Goddard G, Macaluso GM, Mauro G. Topical review: placebo responses and therapeutic responses. How are they related? *Journal of Orofacial Pain* 2009; 23 (2) 93-107
49. Greene CS. Managing the care of patients with temporomandibular disorders: a new guideline for care *Journal of the American Dental Association* 2010; 141 (9) 1086-1088
50. Cairns BE. Pathophysiology of TMD pain - basic mechanisms and their implications for pharmacotherapy *Journal of Oral Rehabilitation* 2010; 37 (6) 391-410
51. Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. Pharmacological interventions for pain in patients with temporomandibular disorders. *Cochrane Database of Systematic Reviews* 2010; CD004715
52. Kimos P, Biggs C, Mah J et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial *Pain* 2007; 127 (1-2) 151-160
53. List T, Axelsson S. Management of TMD: evidence from systematic reviews and meta-analyses *Journal of Oral Rehabilitation* 2010; 37 (6) 430-451
54. Luther F, Layton S, McDonald F. Orthodontics for treating temporomandibular joint (TMJ) disorders *Cochrane Database of Systematic Reviews* 2010; CD006541.
55. Reston JT, Turkelson CM. Meta-analysis of surgical treatments for temporomandibular articular disorders *Journal of Oral Maxillofacial Surgery* 2003; 61:3-10; discussion 10-2
56. Guo C, Shi Z, Revington P. Arthrocentesis and lavage for treating temporomandibular joint disorders. *Cochrane Database of Systematic Reviews* 2009; CD004973
57. Guarda-Nardini L, Ferronato G, Favero L, Manfredini D. Predictive factors of hyaluronic acid injections short-term effectiveness for TMJ degenerative joint disease *Journal of Oral Rehabilitation* 2010 ct 6. doi: 10.1111/j.1365-2842.2010.02164.x. [Epub ahead of print]
58. Guarda-Nardini L, Manfredini D, Ferronato G. Arthrocentesis of the temporomandibular joint: a proposal for a single-needle technique. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2008; 106 (4) 483-486
59. Guarda-Nardini L, Manfredini D, Ferronato G. Short-term effects of arthrocentesis plus viscosupplementation in the management of signs and symptoms of painful TMJ disc displacement with reduction. A pilot study *Oral and Maxillofacial Surgery* 2010; 14 (1) 29-34
60. Guarda-Nardini L, Manfredini D, Stifano M, Staffieri A, Marioni G. Intra-articular injection of hyaluronic acid for temporomandibular joint osteoarthritis in elderly patients *Stomatologija* 2009; 11 (2) 60-65
61. Guarda-Nardini L, Stifano M, Brombin C, Salmaso L, Manfredini D. A one-year case series of arthrocentesis with hyaluronic acid injections for temporomandibular joint osteoarthritis. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 2007;103 (6) e14-22
62. Manfredini D, Bonnini S, Arboretti R, Guarda-Nardini L. Temporomandibular joint osteoarthritis: an open label trial of 76 patients treated with arthrocentesis plus hyaluronic acid injections *International Journal of Oral Maxillofacial Surgery* 2009; 38 (8) 827-834
63. Manfredini D, Guarda-Nardini L, Ferronato G. Single-needle temporomandibular joint arthrocentesis with hyaluronic acid injections. Preliminary data after a five-injection protocol *Minerva Stomatologica* 2009; 58 (10) 471-478

64. Manfredini D, Piccotti F, Guarda-Nardini L. Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature *Cranio* 2010; 28 (3) 166-176
65. Shi Z, Guo C, Awad M. Hyaluronate for temporomandibular joint disorders. *Cochrane Database of Systematic Reviews*. 2003; CD002970.
66. Sidebottom AJ. Guidelines for the replacement of temporomandibular joints in the United Kingdom *British Journal of Oral Maxillofacial Surgery* 2008; 46 (2) 146-147
67. Speculand B. Current status of replacement of the temporomandibular joint in the United Kingdom *British Journal of Oral and Maxillofacial Surgery* 2009; 47 (1) 37-41
68. NICE. *Total prosthetic replacement of the Temporomandibular Joint. Interventional Procedure guidance 239*. 2009; Available from: <http://guidance.nice.org.uk/IPG329> [Accessed 21.01.2011]
69. Kopp S. Neuroendocrine, immune, and local responses related to temporomandibular disorders *Journal of Orofacial Pain* 2001; 15 (1) 9-28